Novartis has paused eight clinical trials of rap-cel, according to a report published on Yahoo Finance's healthcare section.
The pause comes amid broader CAR-T safety concerns across the sector, as noted in the company's announcement. Novartis is a heavyweight in the Swiss SMI index, and major pipeline alterations directly affect its valuation as well as the wider European healthcare sector, according to the feed data.
